Biocon Biologics received U.S. FDA approval for Jobevne, a biosimilar to Bevacizumab, on April 10, 2025, enhancing its oncology product range. This approval marks the seventh biosimilar approved by Biocon in the U.S., with U.S. bevacizumab sales around $2 billion in 2023.